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Herpes simplex virus 1 is a prevalent neurotropic pathogen that infects and establishes latency in peripheral sensory neurons. It can
migrate into the central nervous system and cause encephalitis. ,e association between herpes simplex virus encephalitis and
cerebral venous thrombosis is rare, with a very limited number of case reports described in the literature, despite the recognized
thrombogenic effects of the virus. A 44-year-old man was brought to the emergency department with generalized tonic-clonic
seizures requiring sedation and ventilation to control it. Initial brain computed tomography revealed cortical and subcortical edema
on the left frontal lobe, and a subsequent contrast-enhanced exam showed absence of venous flow over the anterior half of the
superior sagittal sinus. Cerebrospinal fluid polymerase chain reaction was positive for herpes simplex virus type 1, and the patient was
started on acyclovir and anticoagulation, with clinical improvement. Acyclovir administration was maintained for 14 days and oral
anticoagulation for one year, with no recurrence of thrombotic events or other complications. A well-timed treatment has a validated
prognostic impact on herpes simplex encephalitis, making early recognition of its clinical aspects of main importance.
1. Introduction
Herpes simplex virus 1 (HSV-1) infection is common, with a
seropositivity prevalence greater than 60% worldwide [1, 2].
HSV-1 is a neurotropic pathogen that infects and establishes
latency in peripheral sensory neurons, but it can migrate into
the central nervous system with potentially devastating re-
sults. Herpes simplex virus encephalitis (HSE) is an atypical
presentation of the infection, with significant mortality and
morbidity if not promptly recognized and adequately man-
aged [2]. Despite the prothrombotic effects of the virus [3], the
association between HSE and cerebral venous thrombosis
(CVT) is extremely rare, with, to the best of our knowledge,
only three cases described in the literature [4–6].
2. Case Presentation
A 44-year-old white man, with a previous history of gouty
arthritis and type 2 diabetes diagnosed two years earlier, was
admitted to the emergency department for a reported epi-
sode of generalized tonic-clonic seizure at home, lasting
2minutes. ,e patient had no recent history of fever or flu-
like symptoms but reported a moderate occipital headache
in the previous four days. On the initial clinical examination,
the patient was lucid and oriented, hemodynamically stable,
and with fever (auricular temperature of 38°C). A thorough
neurological examination revealed neither meningism signs
nor any focal neurological deficit. Fundoscopic examination
was normal. Apart from evidence of tongue biting, he had no
visible oral or genital vesicular lesions or any skin rash.,ere
were no palpable lymph nodes.
During the observation period in the emergency room,
several convulsive episodes were observed, with postcritical
agitation and disorientation, requiring sedation with pro-
pofol and intubation for airway protection.
A brain computed tomography (CT) scan was per-
formed, revealing cortical and subcortical edema of the left
anterior frontal region and a local linear hyperdensity
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suggestive of a discrete subarachnoid haemorrhage. A ce-
rebral CT venography revealed venous thrombosis in the
anterior two-thirds of the superior longitudinal sinus
(Figure 1).
,e patient had no prior personal or family history of
epilepsy or thrombotic events. ,ere was no history of
cancer. His long-term medication was metformin 700mg
and allopurinol 300mg once a day. He had good metabolic
control of type 2 diabetes with a hemoglobin A1c count of
6.2% and no evidence of end-organ damage. Uric acid was in
the normal range.
Complete blood count and renal and hepatic function
were normal. He had a normal leukocyte count and a red cell
distribution width of 13.9%. Inflammatory markers were
slightly elevated, the erythrocyte sedimentation rate was
43mm/h, and the C-reactive protein was 233.3 nmol/L
(normal <4.76 nmol/L).
Two sets of blood cultures were collected but had no
bacterial growth after 5 days of incubation. An ante-
roposterior view of a chest X-ray was obtained and showed
no evidence of opacities or consolidations. His electrocar-
diogram had a normal sinus rhythm.
,e cytochemical study of cerebrospinal fluid (CSF)
revealed 2 leucocytes/mm3, a protein level of 230mg/L,
and a glucose level of 10mmol/L (serum level of 14mmol/
L). ,e CSF multiplex polymerase chain reaction was
positive for HSV-1 and negative for all the other micro-
organisms tested (HSV-2, enterovirus, varicella zoster
virus, human herpes virus 6, cytomegalovirus, N. menin-
gitidis, H. influenzae, E. coli K1, S. agalactiae, L. mono-
cytogenes, and C. neoformans). Serology for HSV was IgG
positive and IgM negative and negative for both HIV and
syphilis.
,e autoimmune study (antinuclear antibodies, anti-
cardiolipin antibodies, and lupus anticoagulant) was nega-
tive or normal. Complement C3 and C4 test and
homocysteine were normal. Protein C, protein S, and an-
tithrombin III levels were normal. ,e molecular study of
genetic thrombophilias was negative for prothrombin
20210G>Amutation but revealed heterozygosity for factor V
Leiden (mutation 1691G>A).
,e diagnosis of CVTsecondary to HSV-1 infection in a
patient with heterozygosity for factor V Leiden was made.
,e treatment was started with enoxaparin 1mg/kg twice
daily, levetiracetam 1500mg bid, and acyclovir 800mg tid
for 14 days. ,e patient had a positive clinical evolution
during hospitalization, with no more seizures and no
neurological deficits at discharge. ,e selected oral antico-
agulant was rivaroxaban 20mg id, maintained for
12months, without any new convulsive or thromboembolic
episodes registered.
3. Discussion
HSV-1 is estimated to affect more than 60% of world
population and is the main etiological agent of sporadic
encephalitis [1, 2]. ,e diagnosis is suggested by altered
mental status, with or without fever, associated with labo-
ratory and imaging evidence of inflammation of the central
nervous system. A clinical picture of headache, seizures, and
focal neurological deficits should make one think of herpetic
encephalitis. CSFmay usually present moderate lymphocytic
pleocytosis (10–200 lymphocytes/mm3). Brain CT has low
sensitivity and diagnostic specificity, with brain magnetic
resonance imaging (MRI) being the examination of choice
for the diagnosis of encephalitis, although it is not always
available in an emergency room. ,e definitive diagnosis is
made by a positive multiplex PCR for HSV in the CSF. ,is
test has high sensitivity (96%) and specificity (99%) and
supplanted virus cultures as the test of choice for definitive
diagnosis [2]. HSV serology is of little interest in the acute
setting [2].
If clinical suspicion is high, treatment should be initiated
as soon as possible. ,e early introduction of acyclovir is the
modifiable factor with the most significant impact on
prognosis [2]. Empirical treatment is indicated for suspected
cases, given the potential benefit compared to the relative
innocuity of the drug. ,e delay in therapy initiation is one
of the factors responsible for poor prognosis, along with age
and altered mental status at presentation [2]. A dose of
30mg/kg/day (10mg/kg tid) is recommended for 14 to
21 days, depending on the clinical response. Untreated HSV-
1 encephalitis typically had a highmortality rate (about 70%)
that significantly decreased to 5–15% with the advent of
acyclovir [2]. Although it seems to improve the outcome in
animal models, the role of corticosteroids in the treatment of
HSE is not yet well established, and their use is reserved for
situations in which there is significant brain edema andmass
effect [2].
Recurrence is uncommon in adults and is generally less
severe than the initial episode. It is, however, more related to
immune-mediated phenomena than to virus activity itself [2].
,emost frequent complications of HSE are seizures and
brain edema. HSE may rarely present or evolve with in-
tracranial bleeding [7], most often in the form of scattered
petechial haemorrhages. ,is complication may occur even
after the initiation of treatment, and the lack of clinical
improvement or sudden clinical worsening should raise
suspicion of a vascular complication.
Endothelial cell (EC) injury is a common feature of viral
infections and can alter hemostasis.
Herpesviridae infections, particularly, inhibit antico-
agulant functions and induce a procoagulant phenotype.
However, if on one hand the vasculopathy associated with
the varicella zoster virus is well known, having a wide
clinical range that goes from transient ischemic attacks
and cerebral and subarachnoid haemorrhages to spinal-
cord infarction [8], on the other hand the vascular in-
volvement in herpes simplex infections is not so
conspicuous.
,ere are several mechanisms, studied in vitro, that
were proposed as contributing factors to increased
thrombotic risk in HSV infections [3]. By infecting EC,
HSV-1 and HSV-2 reduce heparan sulfate proteoglycan
synthesis and expression, therefore preventing anti-
thrombin III binding to its surface. ,e expression of
thrombomodulin is also reduced, affecting protein C
activation.
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Changes in the EC membrane lead to enhanced
thrombin generation, increasing platelet binding and de-
creasing prostacyclin synthesis. Another mechanism pro-
posed is that HSV infection increases endothelial binding
sites for inflammatory cells and platelets, with subsequent
release of inflammatory cytokines and potentiation of a
prothrombotic EC surface.
Although the prothrombotic effects of HSV-1 are
recognized and debated in the literature, CVT is an ex-
tremely rare event in a proven association with herpetic
encephalitis [3]. To our knowledge, there are only another
three cases reported in the literature (Table 1). All patients
were aged between 30 and 50 years and had a similar
clinical presentation, with seizures and headaches being the
predominant symptoms. In three of the four cases, the
diagnosis of HSE and CVTwas made simultaneously and in
one case [6], there was a clinical worsening during HSE
treatment that led to CVT diagnosis. In two of the cases,
there was an identifiable risk factor for venous thrombo-
embolism. Our patient is the only one that received a direct
anticoagulant as maintenance treatment after the acute
phase. ,ere were no neurological deficits at hospital
discharge in any case nor were any recurrences of the
symptoms reported.
CVT has a prothrombotic risk factor identified in 85%
of the cases [9], either genetic or acquired. Its clinical
manifestations are vast, from headaches to nausea and
vomiting or signs of intracranial hypertension, focal
neurological syndromes, and encephalopathy. ,e di-
agnosis is usually made by contrast-enhanced CT or MRI.
,e therapeutic approach should be anticoagulation, even
in the presence of intracerebral haemorrhage [9–11]. ,e
initiation of anticoagulation should be done with low-
molecular weight heparin or conventional heparin until
the patient is stable and then switching to oral anti-
coagulation with warfarin that should be continued for
3months (in the presence of transient risk factors) or 6–
12months (in the presence of nonmodifiable risk factors).
Indefinite anticoagulation should be considered in the
presence of major risk factors, namely, severe thrombo-
philia (antithrombin deficiency, protein C or S, anti-
phospholipid syndrome, and homozygosity for factor V
Leiden) [11]. Factor V Leiden is the genetic risk factor most
often found in patients with venous thrombosis. Hetero-
zygosity has a prevalence of 3–8% in the European pop-
ulation.,e risk of cerebral venous thrombosis is 3–5 times
normal in heterozygotes [12].
,e role of direct anticoagulants in the anticoagulation of
cerebral thrombotic events is still not consensual. Although its
therapeutic role in pulmonary and lower limb venous
thrombosis is already widely supported and recommended,
cerebral venous thrombosis relies on a considerably different
pathophysiological basis, and its use for this purpose should
be considered off-label [10, 13]. ,e available literature relies
essentially on a small series of clinical cases [11, 14], and
therefore the quality of evidence is still considered very low.
,ere is no evidence of inferiority in relation to warfarin,
either in terms of efficacy or safety [12, 13], but its use requires
close counseling and follow-up. In the described clinical case,
the authors consider that the association of a genetic risk
factor with HSV-1 central nervous system infection caused
the thrombotic event. Anticoagulation with rivaroxaban was
chosen after a multidisciplinary team discussion on the
available therapeutic options.
4. Conclusion
HSV-1 encephalitis in association with CVT is a rare event
with very few cases reported.
,e management of both events requires early thera-
peutic measures with great impact on the prognosis.
,e role of direct oral anticoagulants as a therapeutic
arsenal for thrombotic events is expanding, but its use in the
treatment of CVT requires more scientific support and
should be adapted to each clinical case individually.
(a) (b) (c)
Figure 1: Brain computed tomography images. (a) Initial CT scan reveals loss of cortical-subcortical discrimination in the left frontal
lobe and a local linear hyperdensity indicating subarachnoid haemorrhage. (b) CT venography: sagittal cut showing absence of per-
meability of the anterior two-thirds of the superior longitudinal sinus consistent with thrombosis. (c) 3D reconstruction of the CT
venography.
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Consent
Written informed consent was obtained from the patient for
publication of this case report and the accompanying
images.
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